Bicara Therapeutics BCAX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$157.32M-70.4% | -$137.95M-103% | -$121.52M-104% | -$102.67M-58.3% | -$92.33M-61.8% | ||
| $130K+110% | $105K+87.5% | $77K+40.0% | $68K— | $62K— | ||
| $17.41M+79.5% | $15.01M+103% | $13.74M+176% | $12.16M— | $9.7M— | ||
| -$116.24M-31.7% | -$106.83M-42.9% | -$112.98M-114% | -$100.96M— | -$88.27M— | ||
| $340K+407% | $280K+294% | $82K-82.4% | $48K— | $67K— | ||
| -$217.51M— | -$318.45M— | -$236.16M— | —— | —— | ||
| $195.15M-41.8% | $32.26M-90.4% | $1.03M-99.8% | $334.73M— | $335.33M— | ||
| -$138.6M-141% | -$393.03M-211% | -$253.22M-153% | $328.62M— | $341.88M— | ||
| -$116.58M-32.0% | -$107.11M-43.2% | -$113.06M-112% | -$101M— | -$88.34M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Bicara Therapeutics generate?
- Bicara Therapeutics (BCAX) generated -$116.2M in operating cash flow over the trailing twelve months.
- What is Bicara Therapeutics's free cash flow?
- After $340.0K of capital expenditures, Bicara Therapeutics's free cash flow was -$116.6M over the trailing twelve months, down 32.0% year over year.
- Where does Bicara Therapeutics's cash flow data come from?
- Every line is extracted from Bicara Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.